Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

Abstract Background Genetics-based basket trials have emerged to test targeted therapeutics across multiple cancer types. However, while vemurafenib is FDA-approved for BRAF-V600E melanomas, the non-melanoma basket trial was unsuccessful, suggesting mutation status is insufficient to predict respons...

Full description

Bibliographic Details
Main Authors: Molly J. Carroll, Carl R. Parent, David Page, Pamela K. Kreeger
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Cancer
Subjects:
Reverse phase protein array
Orthogonal partials least squares
Protein activity
Targeted therapies
BRAF inhibitor
Online Access:http://link.springer.com/article/10.1186/s12885-019-6175-2

Internet

http://link.springer.com/article/10.1186/s12885-019-6175-2

Similar Items